DeepakMSahasrabudheMD

Oncology • Rochester, NY

Professor, Medicine, University of Rochester School of Medicine & Dentistry

Join to view full profile

Dr. Sahasrabudhe is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sahasrabudhe's full profile

Already have an account?

Office
601 Elmwood Ave.
Rochester, NY 14642
Phone+1 585-275-5823

Fax+1 585-275-1051

Education & Training

University of RochesterFellowship, Hematology and Medical Oncology, 1980 - 1984
Albany Medical CenterResidency, Internal Medicine, 1977 - 1979
Albany Medical CenterInternship, Internal Medicine, 1976 - 1977
Topiwala National Medical CollegeClass of 1973

Certifications & Licensure

NY State Medical License 1978 - 2026
NC State Medical License 1979 - 2025
WV State Medical License 1976 - 1979
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer Start of enrollment: 1999 Jul 01
Completed
Not Applicable
Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 2
S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 3
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Start of enrollment: 2011 Sep 06
Completed
Phase 1, Phase 2
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 16
Active, not recruiting
Phase 3
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma Start of enrollment: 2018 Jul 17
Active, not recruiting
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

10 citations
Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppre...
Fu-Ju Chou, Changyi Lin, Hao Tian, WanYing Lin, Bosen You
Cell Death & Disease. 2020-11-02
73 citations
Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
Sarah L. Kerns, Chunkit Fung, Patrick O. Monahan, Shirin Ardeshir-Rouhani-Fard, Mohammad Abu Zaid
Journal of Clinical Oncology. 2018-04-04
63 citations
A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome.
Elizabeth Hansen, Deepak M. Sahasrabudhe, Lynn Sievert
Cancer Immunology, Immunotherapy. 2016-04-11

Professional Memberships

American Society of Clinical Oncology - ASCO
Member